Anti-CENPI autoantibodies in scleroderma patients with features of autoimmune liver diseases

Clinica Chimica Acta

Volumn 412, Issue 23-24, 2011, Pages 2267-2271

  Hamdouch, Khaoula ^a,e   Rodríguez, Carmen ^b   Pérez Venegas, José ^c   Rodríguez, Iván ^a   Astola, Antonio ^a   Ortiz, Manuela ^a   Yen, Tim J ^d   Bennani, Mohcine ^e   Valdivia, Manuel M ^a  

^a UNIVERSITY OF CÁDIZ   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DEL MAR   (Spain)

^c HOSPITAL DE JEREZ   (Spain)

^d FOX CHASE CANCER CENTER   (United States)

^e ABDELMALEK ESSAADI UNIVERSITY   (Morocco)

Author keywords

ACA; CENPI; Centromere; Primary biliary cirrhosis; Scleroderma

Indexed keywords

CENPI AUTOANTIBODY; CENPI RECOMBINANT PROTEIN; CENTROMERE ANTIBODY; EPITOPE; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIGEN EXPRESSION; ARTICLE; AUTOIMMUNE DISEASE; BILIARY CIRRHOSIS; COMORBIDITY; CONNECTIVE TISSUE DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; SCLERODERMA; SYMPTOMATOLOGY; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS;

AUTOANTIBODIES; DNA-BINDING PROTEINS; EPITOPES; FLUORESCENT ANTIBODY TECHNIQUE; HUMANS; LIVER DISEASES; SCLERODERMA, SYSTEMIC;

EID: 80053629953     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2011.08.024     Document Type: Article

References (24)

1. Moroi Y., Peebles C., Fritzler M.J., et al. Autoantibody to centromere (kinetochore) in scleroderma sera. Proc Natl Acad Sci U S A 1980, 77:1627-1631.
2. Van Venrooij W.J., Van de Putte L.B. The clinical significance of antinuclear antibodies in connective tissue diseases. Semin Clin Immunol 1991, 2:27-32.
3. Rothfield N.F. Autoantibodies in scleroderma. Rheum Dis Clin North Am 1992, 18:483-498.
4. Earnshaw W.C., Rothfield N. Identification of a family of human centromere proteins using autoimmune sera from patients with scleroderma. Chromosoma 1985, 91:313-321.
5. Rattner J.B., Rao A., Fritzler M.J., et al. CENPF is a ca 400kDa kinetochore protein that exhibits a cell-cycle dependent localization. Cell Motil Cytoskeleton 1993, 26:214-226.
6. Rattner J.B., Rees J., Arnett F.C., et al. The centromere kinesin-like protein CENPE. An autoantigen in systemic sclerosis. Arthritis Rheum 1996, 39:1355-1361.
7. Hsu T.-C., Chang C.-H., Lin M.-C., et al. Anti CENPH antibodies in patients with Sjogren's syndrome. Rheumatol Int 2006, 26:298-303.
8. Saito A., Muro Y., Sugiura K., et al. CENPO a protein localized at the centromere throughout the cell cycle is a novel target antigen in systemic sclerosis. J Rheumatol 2009, 36:781-786.
9. Rodríguez-Bayona B., Ruchaud S., Rodríguez C., et al. Autoantibodies against the chromosomal passenger protein INCENP found in a patient with Graham Little-Piccardi-Lassueur syndrome. J Autoimmun Dis 2007, 4:1.
10. Naparstek Y., Plotz P.H. The role of autoantibodies in autoimmune disease. Annu Rev Immunol 1993, 11:79-104.
11. Okada M., Cheeseman I.M., Hori T., et al. The CENPH-I complex is required for the efficient incorporation of newly synthesized CENPA into centromeres. Nat Cell Biol 2006, 5:446-457.
12. Harrington J.J., Van Bokkelen G., Mays R.W., et al. Formation of de novo centromeres and construction of first-generation human artificial microchromosomes. Nat Genet 1997, 15:345-355.
13. Liu S.T., Hittle J.C., Jablonski S.A., et al. Human CENPI specifies localization of CENPF, MAD1, and MAD2 to kinetochores and is essential for mitosis. Nat Cell Biol 2003, 5:341-345.
14. Bejarano L.A., Bolivar J., Valdivia M.M. Anticentromere antibody specific to human cells directed against the CENPB autoantigen. Cytogenet Cell Genet 1993, 63:54-58.
15. Vazquez-Abad D., Wallace S., Senecal J.L., et al. Anticentromere autoantibodies: evaluation of an ELISA using recombinant fusion protein CENPB as antigen. Arthritis Rheum 1994, 37:248-252.
16. Whyte J., Soriano E., Earnshaw W.C., et al. Frequency of autoantibodies to a major epitope on the carboxyl terminal fragment of CENPB in patients with autoimmune disease. Br J Rheumatol 1995, 34:407-412.
17. Milkiewicz P., Buwaneswaran H., Coltescu C., et al. Value of autoantibody analysis in the differential diagnosis of chronic cholestatic liver disease. Clin Gastroenterol Hepatol 2009, 7:1355-1360.
18. Weiner E.S., Hildebrandt S., Senecal J.-L., et al. Prognostic significance of anticentromere antibodies and anti-topoisomerase I antibodies in Raynaud's disease: a prospective study. Arthritis Rheum 1991, 34:68-77.
19. Earnshaw W.C., Machlin P.S., Bordwell B.J., et al. Analysis of anticentromere autoantibodies using cloned autoantigen CENPB. Proc Natl Acad Sci U S A 1987, 84:4979-4983.
20. Tan E.M., Smolen J.S., McDougal J.S., et al. A critical evaluation of enzyme immuno-assays for detection of antinuclear autoantibodies of defined specificities. I Precision, sensitivity and specificity. Arthritis Rheum 1999, 42:455-464.
21. Norman G.L., Bialek A., Encabo S., et al. Is prevalence of PBC underestimated in patients with systemic sclerosis?. Dig Liver Dis 2009, 41:762-764.
22. Grassegger A., Pohla-Gubo G., Frauscher M., et al. Autoantibodies in systemic sclerosis (scleroderma): clues for clinical evaluation prognosis and pathogenesis. Wien Med Wochenschr 2008, 158:19-28.
23. Prince M.I., Chetwynd A., Craig W.L., et al. Asymptomatic primary biliary cirrhosis: clinical features, prognosis, and symptom progression in a large population based cohort. Gut 2004, 53:865-870.
24. Assassi S., Fritzler M.J., Arnett F.C., et al. Primary biliary cirrhosis (PBC), PBC autoantibodies, and hepatic parameter abnormalities in a large population of systemic sclerosis patients. J Rheumatol 2009, 36:2250-2256.